A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer’s disease and agitated behaviours: the HTA-SYMBAD trialSube Banerjee, Naji Tabet, Susan Stirling et al.|Health Technology Assessment|2023Cited by 8
Cost-effectiveness of mirtazapine for agitated behaviors in dementia: findings from a randomized controlled trialCatherine Henderson, Sube Banerjee, Martín Knapp et al.|International Psychogeriatrics|2022Cited by 4